Dr. John Cush RheumNow
3 years 10 months ago
Dr. Jack Cush discusses the news and journal reports from the past week on RheumNow. This week more lupus nephritis, more drug induced lupus and more lupus infections that may kill.
https://t.co/cpOTUsok7e https://t.co/5Ew7Hr9Mcd
Dr. John Cush RheumNow
3 years 10 months ago
Join Dr. Jack Cush and Dr. Arthur Kavanaugh as they discuss, dissect and deliberate about data presented at the #ACR2022 meeting in Philadelphia.
https://t.co/0DOBvpsV6r https://t.co/T8VrFlu6xq
Dr. John Cush RheumNow
3 years 10 months ago
CONGRATS to Dr Jean Liew: from Bronte scholar to social media influencer https://t.co/f9ZrvxaPgB
Dr. John Cush RheumNow
3 years 10 months ago
RA is an independent risk factor for Thyroid Dz & AITD. Study of 250 RA & 248 non-inflammatory RMD controls. RA had more abnl TFTs (34% v 19%; OR 2.2), Overt hypothyroidism, Anti-TPO Abs, & AITD (21.5% vs 9%; OR 2.8). https://t.co/lRvY4VGkUc https://t.co/ibUqPiD9Bv
Dr. Jack Cush discusses the news and journal reports from the past week on RheumNow. This week more lupus nephritis, more drug induced lupus and more lupus infections that may kill.
Today, Cardinal Health released its third edition of Rheumatology Insights, a research report based on surveys with more than 100 rheumatologists nationwide that focuses on key trends impacting one of the fastest-growing areas of specialty medicine.
Analysis of a national database of hospital discharges from Spain shows that infections accounted for 25% of lupus deaths, making infection the most common cause of death in SLE.
Dr. John Cush RheumNow
3 years 10 months ago
Will we see you there? #ACR2022
What are you most looking forward to on the agenda? https://t.co/KQGHJtwboe
Dr. John Cush RheumNow
3 years 10 months ago
FDA Approves Upadacitinib for Non-Radiographic Axial Spondyloarthritis in patients with objective signs of inflammation who have had an inadequate response or intolerance to tumor necrosis factor (TNF) blocker therapy.
https://t.co/ieaYyznlec https://t.co/YafTOxh8Cr
Dr. John Cush RheumNow
3 years 10 months ago
Update to Axial Spondyloarthritis Guidance
EULAR and the Assessment of SpondyloArthritis International Society (ASAS) has updated their guidance on axial spondyloarthritis (axSpA) management.
https://t.co/XQId2RIaVz https://t.co/vNRYSV2jRh
Dr. John Cush RheumNow
3 years 10 months ago
New ACR/EULAR Guideline Expands RA Remission Definition
Newly released guidance for defining remission in RA is expected to increase the number of patients achieving it while maintaining its ability to predict good objective outcomes.
https://t.co/frGedFHVuU https://t.co/I9B4YjcqLa
Dr. John Cush RheumNow
3 years 10 months ago
Increasing Prevalence of RA, PsA and AS in the UK
Electronic health record (EHR) database analysis from the United Kingdom suggests an increasing number of rheumatoid arthritis (RA), PsA and SpA patients in England.
https://t.co/Rtt5dvFc17 https://t.co/rPsvq3nlXl
Dr. John Cush RheumNow
3 years 10 months ago
Retrospective study of 75 knee OA pts w/ SF aspiration and MRI showed Median SF WBC =284, w/ higher SF WBC w/medium/large effusions. Despite this trend, SF WBC did not strongly correlate w/ MRI inflammation (effusions or synovitis) https://t.co/6suIGJNLdW https://t.co/gNd1Dai4SI
Dr. John Cush RheumNow
3 years 10 months ago
Increasing Risk of Lupus Nephritis
A population based study shows that LN in the US has increased in the last four decades and that LN patients have poorer outcomes with high rates of ESRD and mortality rates 6x that of the general population.
https://t.co/iQ00MnFe2N https://t.co/3z9UrccdM1
